Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.